您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Satralizumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Satralizumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1535963-91-7
包装:5mg
市场价:12600元

产品介绍
Satralizumab 是一种人源化单克隆抗体,是一种有效的白细胞介素 -6 (IL-6) 抑制剂。Satralizumab 可防止褐家鼠的 dTAA 形成和发展。Satralizumab 可用于视神经脊髓炎 (NMOSD) 和降胸主动脉动脉瘤 (dTAA) 的研究。
Cas No.1535963-91-7
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Satralizumab, a humanized monoclonal antibody, is a potentInterleukine-6 (IL-6)inhibitor. Satralizumab prevents dTAA formation and progression in rattusnorvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattusnorvegicus[1].

Animal Model:Rattusnorvegicus(forty, male, 10-week-old, four equal groups)[1]
Dosage:120 mg
Administration:Subcutaneously, once every 2 weeks, for 4 weeks
Result:Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.